- •Nearly all stable coronary patients are on some kind of cardiovascular drug.
- •Despite the use of cardiovascular drugs, a large proportion of patients is still not on risk factor target.
- •In patients with comorbidities, the recommended medication uptake is often not achieved.
- •Physicians should seek for a benefit-risk balance in prescribing medication.
- European cardiovascular disease statistics.
- Cardiovascular disease in Europe 2014: epidemiological update.Eur. Heart J. 2014; 35: 2929
- European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14: S1-113
- European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).Eur. Heart J. 2012; 33: 1635-1701
- 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur. Heart J. 2016; 37: 2315-2381
- Medical management of stable coronary artery disease.Am. Fam. Physician. 2011; 83: 819-826
- Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.Crit. Pathw. Cardiol. 2009; 8: 104-111
- Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.Eur. J. Prev. Cardiol. 2013; 20: 678-685
- Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey.Lancet. 2011; 378: 1231-1243
- EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.Eur. J. Prev. Cardiol. 2016; 23: 636-648
- A new equation to estimate glomerular filtration rate.Ann. Intern. Med. 2009; 150: 604-612
- Defined Daily Dose Index 2019.
- Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007–2010).Am. J. Cardiol. 2013; 112: 1126-1132
- Prescribed medication statistics.(Available from:)https://ec.europa.eu/eurostat/statistics-explained/index.php/Medicine_use_statistics#Prescribed_medicines
- Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.BMC Cardiovasc. Disord. 2016; 16: 115
- Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.J. Am. Coll. Cardiol. 2013; 62: 1791-1801
- The impact of cardiovascular medication use on patients' daily lives: a cross-sectional study.Int. J. Clin. Pharm. 2018; 40: 412-420
- Patient preferences for cardiovascular preventive medication: a systematic review.Heart. 2017; 103: 1578-1586
- Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs.Clin. Med. (Lond.). 2002; 2: 527-533
- Long-term use of cardiovascular drugs: challenges for research and for patient care.J. Am. Coll. Cardiol. 2015; 66: 1273-1285
- Polypharmacy in cardiovascular medicine: problems and promises!.Cardiovasc. Hematol. Agents Med. Chem. 2017; 15: 31-39
- Improving medication adherence in patients with cardiovascular disease: a systematic review.Heart. 2018; 104: 1238-1243